Abstract Library

#4481 Predicting peptide receptor radionuclide therapy (PRRT) response through the landscape of the immune microenvironment in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) often have poor prognosis upon metastasis. Peptide receptor radionuclide therapy (PRRT) is a novel treatment leveraging targeted cytotoxicity of radionuclides to efficiently address primary and metastatic tumours of NETs.

Conference:

Presenting Author: Yu J

Authors: Zeng Z, Lu M, Xie Q, Li J, Yang Z,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumour, tumour immune microenvironment, tumour response, therapeutic effect prediction,

#4398 The role of chromogranin A as a biomarker in neuroendocrine tumours: Diagnostic and prognostic implications

Introduction: Chromogranin A (CgA) is a widely used serum biomarker for neuroendocrine tumours (NETs), reflecting tumour burden and secretory activity. Despite its clinical utility, the diagnostic sensitivity and prognostic value of CgA remain a subject of debate, especially given its potential for false positives and its variation across different NET subtypes.

Conference:

Presenting Author:

Authors: Xu L, Ye M, Zeng X, Chen S, Ding Y,

Keywords: Chromogranin A, neuroendocrine tumour, diagnosis, prognosis, biomarker, Ki-67, metastatic disease,

#4313 Identification of gastroenteropancreatic neuroendocrine tumour patients with high liver tumour burden based on clinicopathological features

Introduction: Metastatic liver tumour burden (LTB) is a prognostic factor affecting the survival of gastroenteropancreatic neuroendocrine tumours (GEP-NETs), but evaluation of the LTB usually depends on radiologic and functional imaging.

Conference:

Presenting Author:

Authors: Jumai N, Chen L, Liu M, He Q, Zeng Z,

Keywords: liver tumour burden, prognosis, GEP-NET,

#3935 Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under the pattern of genomic instability and histological grading

Introduction: Non-functional pancreatic neuroendocrine tumor (NF-Pan-NET) is a kind of highly heterogeneous tumors. Histological grading is the key factors affecting the prognosis of patients and instructive in guiding treatment and assessing recurrence in NF-Pan-NET. 90% of NF-Pan-NET are grade G1 or G2, leading to an unpredictable clinical course that varies from indolent to highly malignant. Approximately one-third of patients without CNV alteration and the prognosis of these patients are better than that of patients with CNV alteration. Therefore, probing the heterogeneity of tumors based on histological grading and CNV variation is crucial.

Conference:

Presenting Author: Ye Z

Authors: Ye Z, Zhou C, Xu X, Chen J, Yu X,

Keywords: Pancreatic neuroendocrine tumor, single-cell sequencing, genomic instability, histological grading,

#3934 The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes

Introduction: Cancer-associated fibroblasts (CAFs) play an important role in a variety of cancers. However, the heterogeneity of CAFs is poorly understood in non-functional pancreatic neuroendocrine tumors (NF-PanNETs). Profiling the heterogeneity of CAFs might reveal the causes of malignant phenotypes in NF-PanNETs.

Conference:

Presenting Author: Ye Z

Authors: Ye Z, Zhou C, Xu X, Chen J, Yu X,

Keywords: nonfunctional pancreatic neuroendocrine tumors, TGF-β, epithelial-mesenchymal transition,